GW Pharmaceuticals plc Reports First Quarter 2017 Financial Results and Operational Progress

– Epidiolex® NDA submission and launch preparation on track –
– New Positive Phase 2 glioma data further demonstrates value of cannabinoid pipeline – 
– Conference call today at 8:30 a.m. EST –

LONDON, Feb. 07, 2017 — GW Pharmaceuticals plc (NASDAQ:GWPH) (GW, the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced financial results for the first quarter ended 31 December 2016.

“As we look forward to 2017, our primary focus is on completing the Epidiolex NDA, which we expect to submit to the FDA in the middle of this year. With three positive Phase 3 trials delivered in 2016, we remain confident in the prospects for Epidiolex’s approval and are accelerating our preparations for a highly successful launch,” stated Justin Gover, GW’s Chief Executive Officer. “Beyond Epidiolex, the value of GW’s

... read more at: